Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

ennl
Careers MediaContact us
ennl
Careers MediaContact us

Investors

Share Price

SEQUANA MEDICAL

ISIN: XXXXXXXXXXXXX-XXXX Updated at 11:05:33

EURO 22.40

XXXXX.XX

+2.18%
SEE THE PRICE CHART

For more information, please consult Euronext

Prev close
21.84
Open
20.60
Volume
17578
Lowest price
10.10
Highest price
20.20
Bid price
20.60
Ask price
20.60
Trading sessions
200
Capitalization
246.01M

Share Data

Status as of 14 November 2024

  • Outstanding share capital: EUR 4,603,936.18
  • Outstanding voting securities: 44,436,192 shares
  • Outstanding voting rights (“denominator”): 44,436,192 voting rights
  • Voting securities that can still be issued: 5,485,289 shares (each share entailing one voting right)
Major Shareholdings

Last update: 18 November 2024

Overview of major shareholdings

This graph represents Sequana Medical’s major shareholders, based on transparency notifications received by the Company, to date.

Overview of transparency notifications received to date

The Belgian Transparency Act refers to article 14 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings in issuers shares of which are admitted to trading on a regulated market and laying down miscellaneous provision.
Pursuant to this Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

For more information and the appropriate transparency forms, please contact Sequana Medical Investor Relations (ir@sequanamedical.com) or the FSMA.

ShareholderDate of notificationTransparency notificationPress release
SFPI-FPIM / Belfius Bank / Belfius Insurance18-Nov-2024Download pdf26-Nov-2024
Sensinnovat BV7-Oct-2024Download pdf10-Oct-2024
Newton Biocapital06-Aug-2024Download pdf9-Aug-2024
Pi Equity30-July-2024Download pdf1-Aug-2024
GRAC29-July-2024Download pdf5-Aug-2024
FPIM-SFPI16-July-2024Download pdf19-July-2024
Adrianus van Herk08-Apr-2024Download pdf11-Apr-2024
EQT Life Sciences Group B.V.10-Apr-2024Download pdf11-Apr-2024
EQT Life Sciences Group B.V.04-Apr-2024Download pdf11-Apr-2024
LSP Management Group B.V.08-Apr-2024Download pdf11-Apr-2024
Optiverder B.V.03-Apr-2024Download pdf08-Apr-2024
Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA02-Apr-2024Download pdf08-Apr-2024
GRAC société simple28-Mar-2024Download pdf08-Apr-2024
ParticipatieMaatschappij Vlaanderen NV03-Apr-2024Download pdf03-Apr-2024
Adrianus van Herk28-Mar-2024Download pdf03-Apr-2024
MCMI19-Jan-2024Download pdf24-Jan-2024
Erik Amble / NeoMed Management / NeoMed IV16-Jan-2024Download pdf24-Jan-2024
Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA11-Jan-2024Download pdf15-Jan-2024
Optiverder BV10-May-2023Download pdf15-May-2023
Participatiemaatschappij Vlaanderen NV11-May-2023Download pdf15-May-2023
NeoMed IV Extension Limited / NeoMed Innovation V Limited06-Feb-2023Download pdf09-Feb-2023
Rosetta Capital Ltd06-Feb-2023Download pdf09-Feb-2023
GRAC société simple22-Mar-2022Download pdf28-Mar-2022
Partners in Equity V B.V.16-Mar-2022Download pdf18-Mar-2022
Newton Biocapital I SA15-Mar-2022Download pdf18-Mar-2022
Sensinnovat BV15-Mar-2022Download pdf18-Mar-2022
NeoMed IV Extension Limited / NeoMed Innovation V Limited14-Mar-2022Download pdf18-Mar-2022
Venture Incubator AG / VI Partners AG19-Feb-2021Download pdf23-Feb-2021
LSP Health Economics Fund Management B.V.19-Feb-2021Download pdf23-Feb-2021
NeoMed IV Extension L.P. / NeoMed Innovation V L.P.19-Feb-2021Download pdf23-Feb-2021
Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA18-Feb-2020Download pdf21-Feb-2020
Capricorn Heath-tech Fund NV / Quest for Growth NV14-Feb-2020Download pdf21-Feb-2020
GRAC Société Simple30-Jan-2020Download pdf03-Feb-2020
NeoMed IV Extension L.P. / NeoMed Innovation V L.P.30-Jan-2020Download pdf03-Feb-2020
Newton Biocapital I Pricav Privée SA21-Feb-2019Download pdf25-Feb-2019
Venture Incubator AG / VI Partners AG21-Feb-2019Download pdf25-Feb-2019
NeoMed IV Extension L.P. / NeoMed Innovation V L.P.20-Feb-2019Download pdf25-Feb-2019
LSP Health Economics Fund Management B.V.19-Feb-2019Download pdf25-Feb-2019
Federale Participatie- en Investeringsmaatschappij N.V.18-Feb-2019Download pdf25-Feb-2019
Participatiemaatschappij Vlaanderen NV18-Feb-2019Download pdf25-Feb-2019
Capricorn Health-tech Fund NV / Quest for Growth NV18-Feb-2019Download pdf25-Feb-2019
Shareholder Meetings

December 20, 2024

Extraordinary General Meeting

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Report of the Board of Directors

Auditor Report

Conclusion Auditor Report

May 23, 2024

Annual and Extraordinary General Meetings

Minutes AGM

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Annual report 2023

XBRL Annual report 2023 – European Single Electronic Format (ESEF) – Dutch only

Statutory annual accounts for the year ended 31 December 2023

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2023

Statutory auditor’s report on the annual accounts for the year ended 31 December 2023

Report of the Board of Directors on the annual accounts for the year ended 31 December 2023

Report of the Board of Directors in accordance with Articles 7:179 and 7:197 of the Belgian Companies and Associations Code (with the report of the statutory auditor in accordance with Article 7:197 of the Belgian Companies and Associations Code)

Special Report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code

Report of the statutory auditor in accordance with Article 7:179 of the Belgian Companies and Associations Code (Dutch language version only)

Draft Remuneration Policy

Advice of the ad hoc committee of independent directors in accordance with Article 7:179 of the Belgian Companies and Associations Code

November 10, 2023

Extraordinary General Meeting

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Special report of the Board of Directors

Report of the Board of Directors

June 26, 2023

Special General Meeting

Minutes SGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

May 25, 2023

Annual General Meeting

Minutes AGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Annual report 2022

Annual report 2022 – European Single Electronic Format (ESEF) – Dutch only

Statutory annual accounts for the year ended 31 December 2022

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2022

Statutory auditor’s report on the annual accounts for the year ended 31 December 2022

Report of the Board of Directors on the annual accounts for the year ended 31 December 2022

Report of the board of directors in accordance with article 7:228 of the Belgian Companies and Associations Code

February 10, 2023

Extraordinary General Meeting

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Report of the Board of Directors

Report of the Statutory Auditor

Remuneration Policy

May 27, 2022

Annual and Extraordinary General Meetings

Minutes AGM

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Annual report 2021

Annual report 2021 – European Single Electronic Format (ESEF) – Dutch only

Statutory annual accounts for the year ended 31 December 2021

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2021

Statutory auditor’s report on the annual accounts for the year ended 31 December 2021

Statutory auditor’s report on the Bootstrap Warrants

Report of the Board of Directors on the annual accounts for the year ended 31 December 2021

Report of the Board of Directors on the renewal of the authorised capital

Report of the Board of Directors on the Bootstrap Warrants

Remuneration Policy

May 27, 2021

Annual and Extraordinary General Meetings

Minutes AGM

Minutes EGM

Convening Notice

Attendance Form NL/EN

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights NL/EN

Annual report 2020

Statutory annual accounts for the year ended 31 December 2020

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2020

Statutory auditor’s report on the annual accounts for the year ended 31 December 2020

Statutory auditor’s report on the 2021 Share Options (full version in Dutch only)

Report of the Board of Directors on the annual accounts for the year ended 31 December 2020

Report of the Board of Directors on the renewal of the authorised capital

Report of the Board of Directors on the 2021 Share Options

May 28, 2020

Annual and Extraordinary General Meetings

Minutes AGM

Minutes EGM

Convening Notice

Explanatory Note

Proxy Form NL/EN

Vote by Letter Form NL/EN

Outstanding Shares and Voting Rights

Annual report 2019

Statutory annual accounts for the year ended 31 December 2019

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2019

Statutory auditor’s report on the annual accounts for the year ended 31 December 2019

May 23, 2019

Annual General Meeting

Minutes

Invitation

Explanatory Note

Proxy Form NL/EN

Vote by Mail Form EN / Vote by Mail Form NL (please complete the Dutch form)

Outstanding Shares and Voting Rights

Attendance Form EN / Attendance Form NL (please complete the Dutch form)

Annual report 2018

Statutory annual accounts for the year ended 31 December 2018

Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2018

Statutory auditor’s report on the annual accounts for the year ended 31 December 2018

April 25, 2019

Extraordinary General Meeting

Minutes NL

Invitation

Explanatory Note

Proxy Form EN / Proxy Form NL (please complete the Dutch form)

Vote by Mail Form EN / Vote by Mail Form NL (please complete the Dutch form)

Outstanding Shares and Voting Rights

Attendance Form EN / Attendance Form NL (please complete the Dutch form)

Other Regulated Information

November 14, 2024

Article 7:198 juncto articles 7:179 and 7:197 of the Belgian companies and Associations Code

Board Report (Dutch)

Belfius Loan Conversion – Auditor Report art.7:179 (Dutch)

Belfius Loan Conversion – Auditor Report art.7:197 (Dutch)

October 21, 2024

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Retention Shares – Board Report (Dutch)

Retention shares – Auditor Report (Dutch)

July 5, 2024

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Retention Shares – Board Report (Dutch)

Retention shares – Auditor Report (Dutch)

March 25, 2024

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor (Dutch only)

November 6, 2023

Article 7:198 juncto articles 7:180 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors (Dutch only)

Report of the Statutory Auditor (Dutch only)

October 4, 2023

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors (Dutch only)

Report of the Statutory Auditor (Dutch only)

April 24, 2023

Article 7:198 juncto articles 7:179, 7:180 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor

March 07, 2022

Article 7:198 juncto articles 7:179, 7:191 and 7:193 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor

March 25, 2021

Article 7:198 juncto articles 7:179 and 7:197 of the Belgian companies and Associations Code

Report of the Board of Directors – Dutch only

Report of the Statutory Auditor – Dutch only

February 9, 2021

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor – full version in Dutch only

January 27, 2020

Article 7:198 juncto articles 7:179 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor on the proposal of a capital increase (within the framework of the authorized capital) with cancellation of the preferential subscription right – full version in Dutch only

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES